Boston Scientific announces results for second quarter 2026

Boston Scientific delivered strong Q2 growth, boosted buybacks, and made a major strategic investment.

What the company is saying

Boston Scientific highlights robust financial performance for the second quarter of 2026, emphasizing net sales of $5.442 billion and 7.5% reported growth. The company frames its narrative around year-over-year improvements in GAAP net income ($907 million) and adjusted EPS ($0.86), positioning these as evidence of operational strength. Management draws attention to the completion of a $2 billion accelerated share repurchase and a $1.5 billion investment in MiRus LLC, presenting these as shareholder-friendly and growth-oriented actions. Regional and segment growth figures are foregrounded, with particular mention of the 22.4% reported growth in Latin America and Canada. The announcement also references regulatory and clinical milestones, such as FDA 510(k) clearance and trial presentations, but provides little detail on these items. The tone is confident and data-driven, with Mike Mahoney, chairman and CEO, cited as the key spokesperson.

What the data suggests

The disclosed numbers confirm a clear upward trajectory: net sales increased from $5,061 million in Q2 2025 to $5,442 million in Q2 2026, a 7.5% rise. GAAP net income attributable to common stockholders grew from $797 million to $907 million, and GAAP EPS improved from $0.53 to $0.61. Adjusted EPS climbed from $0.75 to $0.86, reflecting both revenue growth and margin expansion. Segment data shows Cardiovascular up 8.3% and MedSurg up 5.9% reported, while regional data highlights double-digit growth in Asia-Pacific (11.2%) and Latin America/Canada (22.4%). Gross profit rose to $3,848 million, and operating income reached $1,178 million. The company completed a $2 billion share buyback and invested $1.5 billion for a 34% MiRus LLC stake, both confirmed by the data. Guidance for full-year 2026 net sales growth (5.5-6.5% reported) and adjusted EPS ($3.28-$3.32) is consistent with recent performance. Claims about clinical trial success and regulatory clearance lack supporting numbers or documentation.

Analysis

The announcement is primarily focused on realised financial results, with detailed disclosure of net sales, GAAP net income, adjusted EPS, and segment/regional growth, all supported by numerical evidence. The majority of key claims are backward-looking and substantiated by the provided data, including year-over-year improvements in both top-line and bottom-line metrics. Forward-looking statements are limited to standard guidance for the next quarter and full year, which is typical for quarterly results and does not constitute hype. The $1.5 billion investment in MiRus LLC is disclosed as completed, and the $2 billion share repurchase program is also reported as completed, so there is no capital intensity risk paired with long-dated, uncertain returns. The tone is positive but proportionate to the actual results, with no evidence of narrative inflation or overstatement.

Risk flags

• ●The company does not provide reconciliations of forward-looking adjusted EPS guidance to GAAP due to unpredictability of certain charges, including litigation and restructuring. This limits visibility into potential downside from non-operating items and could mask volatility in reported earnings.
• ●Claims regarding clinical trial outcomes and regulatory milestones are not substantiated with numerical data or supporting documentation. This lack of transparency makes it difficult to assess the true commercial or clinical significance of these developments.
• ●The $1.5 billion investment in MiRus LLC represents a substantial capital allocation for a minority stake and an option on a future acquisition. The financial return and strategic value of this investment are uncertain, as no revenue or profitability projections for MiRus or its TAVR business are provided.

Bottom line

Boston Scientific’s Q2 2026 release demonstrates strong operational and financial momentum, with clear year-over-year gains in revenue, net income, and EPS. The $2 billion share repurchase and $1.5 billion MiRus LLC investment signal both capital return and growth ambitions, though the latter’s payoff is unquantified. While the company’s financial disclosures are detailed and credible, operational claims about clinical and regulatory milestones are not backed by data, limiting their investment relevance. The absence of GAAP reconciliation for forward guidance introduces some earnings quality uncertainty. For investors, the core story is robust near-term execution and prudent capital management, but the long-term impact of the MiRus investment and pipeline milestones remains to be proven. The most important takeaway is that Boston Scientific is delivering on its financial promises, but further detail is needed to evaluate the upside from new products and strategic bets.

Announcement summary

(NYSE: BSX) Boston Scientific Corporation generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted EPS of $0.86 for the period, compared to $0.75 a year ago. Boston Scientific completed a $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares, and invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and exclusive option to acquire the MiRus TAVR business. Net sales growth by segment included MedSurg at 5.9 percent reported and Cardiovascular at 8.3 percent reported, while regional growth included United States at 6.2 percent and Latin America and Canada at 22.4 percent reported. The company now estimates net sales growth for the full year 2026 to be approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis, with adjusted EPS guidance of $3.28 to $3.32. Boston Scientific received U.S. Food and Drug Administration 510(k) clearance for the TruSelect™ 2.6 Microcatheter and presented late-breaking clinical trial results for several investigational devices. The company commenced enrollment in the pivotal FARADIGM clinical trial and announced clinical trial results at Heart Rhythm 2026.

Disagree with this article?